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ABSTRACT
Transfer RNAs (tRNAs) are non-coding RNA
molecules essential for protein synthesis. Post-
transcriptionally they are heavily modified to im-
prove their function, folding and stability. Intronic
polymorphisms in CDKAL1, a tRNA methylthiotrans-
ferase, are associated with increased type 2 diabetes
risk. Loss-of-function mutations in TRMT10A, a tRNA
methyltransferase, are a monogenic cause of early
onset diabetes and microcephaly. Here we confirm
the role of TRMT10A as a guanosine 9 tRNA methyl-
transferase, and identify tRNAGln and tRNAiMeth as
two of its targets. Using RNA interference and in-
duced pluripotent stem cell-derived pancreatic -like
cells from healthy controls and TRMT10A-deficient
patients we demonstrate that TRMT10A deficiency
induces oxidative stress and triggers the intrin-
sic pathway of apoptosis in -cells. We show that
tRNA guanosine 9 hypomethylation leads to tRNAGln
fragmentation and that 5′-tRNAGln fragments medi-
ate TRMT10A deficiency-induced -cell death. This
study unmasks tRNA hypomethylation and fragmen-
tation as a hitherto unknown mechanism of pancre-
atic -cell demise relevant to monogenic and poly-
genic forms of diabetes.
INTRODUCTION
tRNAs are non-coding RNA molecules essential for pro-
tein synthesis. After transcription, tRNAs undergo nu-
clear maturation involving 5′ leader sequence removal, 3′
trailer trimming, CCA addition, intronic splicing, and post-
transcriptional modifications that modulate their function,
folding and stability (1,2). More than 90 different tRNA
modifications have been described inmammals. Thesemod-
ifications are introduced by nuclear, cytosolic or mitochon-
drial tRNA-modifying enzymes. Up to 20% of cytoplasmic
tRNA nucleosides are modified, most often by methylation
(2). The biological role of most tRNA modifications re-
mains unknown. Modifications in or around the anticodon
(at positions 34 and 37) play an important role in decod-
ing accuracy and maintenance of the reading frame (3–5).
Modifications within the tRNA bodymodulate tRNA fold-
ing, stability and amino-acylation (2,6). tRNAs are among
the most stable RNA species in vivo, but reduced tRNA
modifications may lead to their degradation (7–9) or frag-
mentation by endonucleases (10). Angiogenin-mediated
cleavage at the anticodon generates 29–50 nucleotide-long
5′- and 3′-tRNA halves also called tRNA-derived stress-
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induced RNAs (tiRNAs) (10–12). Shorter tRNA fragments
(tRFs) of 14–30 nucleotides are generated by Dicer, Dgcr8
(13) and possibly other endonucleases (14). tRNA frag-
mentation is a stress-regulated process that is positively or
negatively tuned by the presence of tRNA modifications
(15–17). Extensive human genetic evidence has linked loss-
of-function mutations in tRNA-modifying enzymes with
cancer, neurological disorders, mitochondrial disease and
diabetes (10,18). Mitochondrial tRNA (mt-tRNA) muta-
tions that hinder tRNA modifications cause mitochon-
drial dysfunction and maternally inherited diabetes (19).
Intronic polymorphisms in CDKAL1 are associated with
type 2 diabetes (T2D) risk and reduced insulin secretion
(20–22). CDKAL1 catalyzes the 2-methylthio (ms2) mod-
ification of N6-threonyl carbamoyl adenosine (t6A) in po-
sition 37 of tRNALys(UUU) (23), an essential modification
to prevent codon misreading. In pancreatic -cells, CD-
KAL1 deficiency and reduced tRNALys(UUU) ms2 affect ly-
sine incorporation into proinsulin and impair proinsulin
processing, leading to endoplasmic reticulum (ER) stress
and glucose intolerance in mice (23). Missense mutations in
TRMT10A lead to early-onset diabetes, microcephaly and
intellectual disability (24–29). TRMT10A is the homologue
of yeast Trm10, a methyltransferase that methylates guano-
sine at position 9 (m1G9) of selected tRNA species (30,31).
TRMT10A is a nuclear protein, ubiquitously expressed but
enriched in pancreatic islets and brain, the two main tissues
affected in patients. We showed that TRMT10A deficiency
sensitizes -cells to apoptosis (24). In vitro methylation as-
says using recombinant human TRMT10A suggested that,
as Trm10, TRMT10A has m1G9 tRNA methyltransferase
activity (27,32). Here we set out to elucidate the role of
human TRMT10A and identify the molecular mechanisms
underlying TRMT10A deficiency-induced -cell death and
diabetes.
MATERIALS AND METHODS
Cell culture
Rat INS-1E cells (kindly provided by Prof. Wollheim, Uni-
versity of Geneva, Switzerland) were cultured in RPMI-
1640 medium with GlutaMAX-I (ThermoFisher) and 5%
FBS as previously described (33). Human clonal EndoC-
H1 cells (kindly provided by Prof. Scharfmann, Univer-
site´ Paris-Descartes, France) were cultured in low glucose
DMEM (ThermoFisher) as described (34,35). The same
medium with 2% FBS was used for cell treatment (35).
Lymphoblasts were obtained from three healthy individu-
als, four patients with homozygous TRMT10A mutations
from two families (24,26) and three heterozygous carriers.
Patients PA-1 and 2 and the heterozygous carrier of family
1 had a c.379G>A; p.Arg127Stop mutation in TRMT10A
(24). Patients PA-3 and -4 and two heterozygous carriers
from family 2 had a c.79G>T; p.Glu27Stop mutation (26).
Lymphoblasts were cultured in RPMI-1640 medium sup-
plemented with 20% FBS, 100 mU/ml penicillin and 100
mU/ml streptomycin. Human islets from non-diabetic or-
gan donors (n= 6, age 60± 5 years, bodymass index 27± 2
kg/m2) were isolated by collagenase digestion and density
gradient purification in Pisa, Italy (36) and cultured, dis-
persed and transfected as previously described (37). -cell
purity, determined by immunofluorescence, was 44 ± 3%.
Human induced pluripotent stem cell differentiation into -
like cells
Fibroblasts were obtained after informed consent, with ap-
proval by the Ethics Committees of the Helsinki and Uusi-
maa Hospital District (no. 423/13/03/00/08) and the Eras-
mus Hospital, and reprogrammed into induced pluripo-
tent stem cells (iPSCs) using Sendai Virus technology (38).
The control iPSC lines HEL46.11 (CT1) (38) and HEL
115.6 (CT2) were derived from human neonatal foreskin
(38) and umbilical cord fibroblasts, respectively. The lat-
ter were obtained from an unborn male fetus of 31 weeks
diagnosed with a lymphangioma of the face. In this indi-
vidual, microarray-based comparative genomic hybridiza-
tion was normal ruling-out large chromosomal rearrange-
ments. The TRMT10A-deficient iPSC line HEL122.2 was
derived from adult skin fibroblasts. All iPSC lines were cul-
tured in Matrigel-coated plates (Corning BV, Life Sciences)
in E8 medium (Life Technologies) and passaged with 0.5
mM EDTA (Life Technologies) twice per week. For -cell
differentiation we used a modified protocol based on ear-
lier studies (38–40). Briefly, iPSCs were washed once with
0.5 mM EDTA, incubated with Accutase (Capricorn Sci-
entific) for 3–8 min and seeded at 1.5–2.5 million cells/3.5
cmMatrigel-coated wells with E8medium containing 5M
ROCK inhibitor (StemCell). The 7-stage differentiationwas
initiated when cell culture reached confluency, 24 or 48 h
after plating. iPSCs were washed once with PBS and cul-
tured with stage 1 differentiation medium. Differentiation
continued until the end of stage 4 in Matrigel-coated wells.
At the end of this stage the cells were washed twice with 0.5
mM EDTA, detached by 5–10 min incubation with Accu-
tase and spun down for 3 min at 250 RCF. The cells were
then resuspended in stage 5 medium, containing 10 M
ROCK inhibitor, at a density of 10 million cells/ml in ultra-
low attachment 6-well plates (Corning) and kept in suspen-
sion by continuous rotation at 100 rpm in the 5% CO2 incu-
bator, forming compact aggregates 24 hours after plating.
The cells were further cultured in stage 5 medium without
ROCK inhibitor. Until day 15 of differentiation medium
was freshly prepared and changed daily. From day 16 until
the end of the differentiation medium was refreshed every
second day. The composition of the media is described in
Supplementary Tables S3 and S4.
Embryoid body differentiation
The spontaneous differentiation capacity of control
HEL115.6 (CT2) and TRMT10A-deficient HEL122.2
iPSCs was evaluated by in vitro embryoid body differenti-
ation. The spontaneous differentiation capacity of control
iPSCs HEL46.11 (CT1) has been previously reported
(38). For embryoid body differentiation the iPSCs were
cultured in E8 until 80% confluency, washed twice with
0.5 mM EDTA and detached by 5 min incubation with
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Accutase. The cells were resuspended and plated in ultra-
low attachment six-well plate in embryoid body medium
(Supplementary Table S5) containing ROCK inhibitor,
and kept in suspension by continuous rotation at 100
rpm in the 5% CO2 incubator. Twenty four hours after
plating, the ROCK inhibitor was removed. The embryoid
bodies were left to differentiate in suspension for two weeks
with medium change every second day. After 2 weeks, the
embryoid bodies were plated in eight-well chamber slides,
let to attach and outgrow for two more weeks after which
the cells were fixed for immunofluorescence.
Cell transfection
For RNA interference, INS-1E, EndoC-H1 cells and dis-
persed human islets were transfected overnight with 30
nM control siRNA (Qiagen), not interfering with -cell
function or gene expression (37), or siRNAs targeting rat
or human TRMT10A, rat Bim and Bad (41) and hu-
man Bim (ThermoFisher). For transfection of tRNA frag-
ments, EndoC-H1 cells were incubated overnight with
30 nM control siRNA (Qiagen), 5′tiRNAGln or 5′tRFsGln
in its sense (SS) or antisense (AS) version. The stabi-
lized 5′tRFsGln AS was used at 120 nM. siRNA, tRFs-
and tiRNAs-lipid complexes were formed in Opti-MEM
medium and transfected using Lipofectamine RNAiMAX
or 2000, respectively (ThermoFisher). siRNA, tiRNAs,
tRFs and stabilized 5′tRFsGln AS sequences and lipofec-
tamine concentrations are provided in Supplementary Ta-
bles S6–S8.
Cell treatment and apoptosis assays
iPSC-derived -like cells were exposed to the synthetic ER
stressor thapsigargin (1 M). The ROS scavengersN-acetyl
L-cysteine (NAC) and 4,5-dihydroxy-1,3-benzenedisulfonic
acid (Tiron) were used at 1 mM and 25 M, respectively.
Apoptosis was detected by fluorescence microscopy af-
ter staining with the DNA binding dyes Hoechst 33342 (5
g/ml, Sigma Aldrich) and propidium iodide (5 g/ml,
Sigma Aldrich) (24). Cell death was determined in at least
600 cells by two observers, one of them unaware of the ex-
perimental conditions. Early and late apoptosis was also as-
sessed byReal time-Glo™AnnexinV apoptosis and necrosis
assay (Promega) that uses equimolar ratios of twoAnnexin-
V fusion proteins containing complementary subunits of
NanoBiT® Luciferase, and a fluorescent DNA-binding
probe. Apoptosis was confirmed by immunofluorescence
for cleaved caspase-3, Western blots for cleaved caspase-
9, and mitochondrial cytochrome c release. The separation
of cytosolic and mitochondrial fractions was performed in
cytosolic lysis buffer (75 mM NaCl, 1 mM NaH2PO4, 8
mM Na2PO4, 250 mM sucrose, 21 g/l aprotinin, 1 mM
PMSF) containing 0.8 g/l digitonin (Sigma Aldrich).
RNA extraction
Poly(A)+ RNA was isolated using oligo-dT 25-coated
polystyrene Dynabeads (Life Technologies) and used for
real-time PCR. For total RNA extraction cells were washed
with PBS and lysed in Qiazol. The lysate was then loaded
into QIAshredder column to break DNA, and small (<200
nucleotides) and long (>200 nucleotides) RNAs were puri-
fied using miRNeasy kit (Qiagen) following the manufac-
turer’s instructions. Small RNAs were used for subsequent
applications or tRNA purification. RNA was quantified by
nanodrop and quality was evaluated by an Agilent Bioana-
lyzer (Agilent) using the Small RNA Analysis kit.
tRNA purification
tRNA was purified using NucleoBond Xtra resin
(Macherey-Nagel) as described (42). Briefly, small RNAs
were mixed with an equal volume of equilibration buffer
(50 mM Tris-H3PO4 pH 6.3, 15% ethanol, 300 mM
KCl), loaded into the NucleoBond column, extensively
washed with equilibration buffer and eluted with 100 mM
Tris-phosphate pH 6.3, 15% ethanol, 650 mM KCl while
monitoring the absorbance at 260 nm was monitored.
Fractions corresponding to the peak absorbance were
pooled, and tRNAs were precipitated by adding 0.7 vol-
ume of isopropanol for 1 h at 4◦C, followed by 30 min
centrifugation at 20000 RCF at 4◦C. The pellet was washed
once with 70% ethanol and resuspended in RNA-free
water. The integrity of purified tRNA was analyzed by
denaturing 15% acrilamide gel.
Retrotranscription and real-time PCR
mRNA and long RNA fractions were reverse transcribed
as described (24). Real-time PCR was performed using
Rotor-Gene SyBR Green on a Rotor-Gene Q cycler (Qia-
gen) or using IQ SYBR Green Supermix on a MyiQ2 in-
strument (Bio-Rad). Standards were prepared in a conven-
tional PCR. Gene expression was calculated as copies/l
using the standard curve approach (24). Expression values
were corrected for the reference genes GAPDH or -actin,
which were not modified by the experimental conditions.
The primers used for real-time PCRand to prepare the stan-
dards are provided in Supplementary Tables S9 and S10.
Assessment of guanosine methylation by high-performance
liquid chromatography coupled to tandem mass spectrometry
m1G was quantified by high-performance liquid chro-
matography (HPLC) coupled, through electrospray ioniza-
tion, to tandem mass spectrometry (MS) in total RNA
and tRNA from lymphoblasts from control individuals,
heterozygous mutations carriers and TRMT10A-deficient
patients. RNA samples were digested into single nucle-
osides by overnight incubation with nuclease P1 (Sigma
Aldrich) and alkaline phosphatase treatment as previously
described (43). HPLC-tandemMS analyses were performed
with an Accela chromatographic system coupled to a triple
quadrupole Quantum Ultra apparatus (Thermo Electron
SAS) equipped with an HESI electrospray source used in
the positive ionization mode. HPLC separation was car-
ried out with a 2 × 150-mm octadecylsilyl silica gel (3-mm
particle size) column (Uptisphere Interchim, Montluc¸on,
France) and a 0–20% linear gradient of acetonitrile in 0.1%
formic acid over 20 min as the mobile phase. MS detec-
tion was performed in the multiple reactions monitoring
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mode to obtain high sensitivity and specificity. The transi-
tions used to detect m1G and parent guanosine (Guo) were
298→166 and 284→168, respectively. Guo was eluted at
13.2 min, whereas retention time of m1G was 15.7 min. For
both m1G andGuo, quantification was performed by exter-
nal calibration, and the results are given as the number of
m1G per 1000 Guo.
Radioactive labeling of oligonucleotides
Oligonucleotides used for primer extension assays and
DNA probes used in northern blots were 5′-end-labeled us-
ing ATP [ -32P] and T4 polynucleotide kinase (T4 PNK)
(ThermoFisher). The labeling reaction was performed by
mixing 20 pmol oligonucleotide primers or 200 ng DNA
probes with 150 Ci ATP [ -32P], 2 l 10× T4 PNK re-
action buffer, 10U T4 PNK and DEPC-treated water up to
20 l. Samples were incubated at 37◦C for 1 h, and the re-
action was stopped by addition of 5 l EDTA (0.5 mM pH
8.0) and 2 min heating at 95◦C.
Detection of guanosine 9 methylation in tRNAs
The presence of m1G9 was examined by primer extension
assays in lymphoblast tRNA, as described (31). 1 pmol of
[ -32P]ATP-labeled tRNA-specific primers (sequences are
provided in Supplementary Table S11) was annealed to 500
ng of purified tRNAs in the presence of 50 mM Tris–HCl
pH 8.3, 30 mMNaCl and 10 mMDTT by 2–3 min denatu-
ration at 95◦C followed by slow cool down to 37◦C. For the
primer extension assays and manual sequencing, 100 ng of
annealed tRNA/primers were mixed with 5 mMMgCl2, 1x
buffer (GeneCraft), 2.5 UMuLV reverse transcriptase (Ap-
plied Biosystems), 1 U RNase inhibitor (Applied Biosys-
tems), 2 mM dNTPs (Eurogentec). Manual sequencing was
performed by selective incorporation of chain-terminating
dideoxynucleotides (ddNTPs). Four separate reactions (A,
C, G and T) were performed by adding 2.5 mM of one
of the chain-terminating ddNTP (ddATP, ddCTP, ddGTP
or ddTTP), 0.05 mM of the corresponding dNTP (dATP,
dCTP, dGTP or dTTP) and 0.1 mM of the other three
dNTPs. Primer extension and sequencing reactions were in-
cubated for 1 h at 42◦C for reverse transcription. The re-
actions were stopped by adding 7 l loading buffer con-
taining 90% formamide, 18.6% EDTA, 0.1% xylene cyanol,
0.1% bromophenol blue and 10% glycerol. The amplicons
were separated in 15% polyacrylamide gels containing 4
M urea. The gels were then fixed in 1× TBE containing
10% methanol and 10% ethanol, and autoradiography per-
formed using Amersham Hyperfilm MP (GE Healthcare)
with TranScreen HE intensifying screen (Kodak). The films
were manually developed using Carestream developer and
fixator solutions (Kodak).
For the real-time PCR-based detection of m1G9, 40–50
ng small RNAs were annealed with specific reverse primers
and reverse transcribed. cDNAwas then used as template in
real-time PCR using the primer combinations (Fw1 + Rev)
and (Fw2 + Rev). In Fw1 primers an overhang sequence
was added to the 5′ end to allow the annealing of the primer
upstream the G9 in tRNA sequences. As in the primer ex-
tension assays, the presence of m1G9 blocks reverse tran-
scription generating shorter amplicons. As primer Fw1 tar-
gets the 5′ end of the tRNA, in the presence of m1G9 no
PCR amplification will be obtained using the primer pair
Fw1 + Rev. The PCR amplification using primer pair Fw2
+Rev is not altered by the presence or absence ofm1G9; this
pair was used as reference. Primer sequences are provided in
Supplementary Table S12. The data analysis was performed
using the 2−Ct method according to the formula:
Calculation for lymphoblasts and iPSC-derived -like
cells:
Ct =
(
Ct(Fw1+Rev) − Ct(Fw2+Rev)
)
Patient or control
−
(
Ct(Fw1+Rev) − Ct(Fw2+Rev)
)
AVGControls
where AVG Controls is the average of the Ct of two to
three controls.
Calculation for TRMT10A-silenced EndoC- H1 cells:
Ct = (Ct(Fw1+Rev) − Ct(Fw2+Rev))siTRMT10Aor siCT
−(Ct(Fw1+Rev) − Ct(Fw2+Rev))siCT
In both assays, tRNAHis that contains a C in position 9
was used as negative control.
Northern blot
tRNA fragmentation was examined by Northern blot
adapting a previously described protocol (44). 10 g short
(<200 bp) RNA was denatured in formamide and run
in 15% polyacrylamide-8 M urea gels at 120V for 2–3 h.
RNA was transferred to positively charged nylon mem-
brane (ThermoFisher) through electroblot transfer per-
formed at 250mA for 2 h, followed by 350mA for 1 h at 4◦C
in 0.5× TBE. Membranes were crosslinked by short-wave
UV light, pre-hybridized for 2 h in hybridization solution
(5x SSC, 1x Denhardt’s solution (Sigma Aldrich), 7% SDS,
20 mM Na2PO4) at 46◦C, and then hybridized overnight
at 46◦C with 10 ng/ml [ -32P]ATP-labeled tRNA-specific
DNA probes complementary to 5′ or 3′ halves of tR-
NAs. Probe sequences are provided in Supplementary Ta-
ble S13. Membranes were washed in 2x SSC/0.1% SDS, 1x
SSC/0.1% SDS and 0.1x SSC, air-dried and radioactive sig-
nal detected by autoradiography.
Quantification of tRFs by real-time PCR
For tRNA fragment quantification total RNA was purified
using the miRNeasy kit (Qiagen) as previously described.
Before reverse transcription, total RNA samples were sub-
jected to 2′–3′ cyclic phosphate removal and 5′ hydroxyl
group phosphorylation using rtStar™ tRF and tiRNA pre-
treatment Kit (ArrayStar), followed bym1A, m3C andm1G
demethylation using recombinant Escherichia coli AlkB
demethylase, and its mutant AlkB-D135S (45). Plasmids
coding for the wild type and mutated enzymes were a gift
from Tao Pan (pET30a-AlkB Addgene plasmid #79050,
pET30a-AlkB-D135S Addgene plasmid # 79051). The re-
combinant His-tagged proteins were purified usingHisLink
protein purification resin (Promega). After treatment, the
RNA samples were polyadenylated and reverse transcribed
D
ow
nloaded from
 https://academ
ic.oup.com
/nar/advance-article-abstract/doi/10.1093/nar/gky839/5104737 by Library - D
uncan of Jordanstone user on 11 O
ctober 2018
Nucleic Acids Research, 2018 5
using miRCURY LNA RT kit (Exiqon) and a poly(T)
primer with a 3′ degenerate anchor and a 5′ universal tag.
tRNA-derived fragments were quantified by real-time PCR
using miRCURY LNATM SYBER Green PCR Kit (Ex-
iqon), and specific custom-designed miRNA LNA™ PCR
primers targeting the first 17 nucleotides of tRNAGln and
hsa-let-7f-5p, used as housekeeping.
tRNA aminoacylation
Ten millon lymphoblasts were incubated for 15 min in
2 ml methionine- or glutamine-free RPMI-1640 supple-
mented with 10% dialyzed FBS, and then incubated for
10 min in the same medium containing 10 Ci/ml L-[35S]-
methionine or L-[3,4–3H(N)]-glutamine at 37◦C. Cells were
then centrifuged 4 min at 1400 rcf, washed twice with PBS,
resuspended in acidic solution (50 mM NaOAc, 10 mM
MgCl2, 150mMNaCl pH 4.5) to preserve amino-acylation,
and lysed by the addition of an equal volume acidic phe-
nol:chloroform (Invitrogen). After 2 h, samples were cen-
trifuged at 7000 RCF and the RNA from the aqueous phase
precipitated with isopropanol. The pellet was dissolved in
the same acidic solution. A fraction of the samples was in-
cubated for 1 h at 37◦C with 100 mM Tris–HCl pH 8.9
to ensure the complete deaminoacylation of tRNAs; these
samples were used as negative controls. RNA was then re-
precipitated with 100% ethanol and the pellet dissolved in
200 l acid solution. 5 l was used for RNA quantifica-
tion by nanodrop and 180 l used for L-[35S]-methionine or
L-[3,4–3H(N)]-glutamine detection in a liquid scintillation
analyzer (Packard). tRNA charging was expressed as disin-
tegration per minutes (DPM) divided by RNA content in
each sample.
Detection of intracellular reactive oxygen species
ROS were measured with the oxidation-sensitive fluores-
cent probes dichloro-dihydro-fluorescein diacetate (DCF)
and hydroxyphenyl fluorescein (HPF) (ThermoFisher) in
cells cultured in poly-lysine-coated black plates. The cells
were loaded with 10 M DCF or HPF for 20 min, washed
twice with PBS andmeasured in aVICTORmultilabel plate
reader (PerkinElmer) using excitation and emission spectra
of 485 and 535 nm. As a positive control, cells were treated
for 2 h with 15 Mmenadione.
Measurements of cytosolic H2O2 using roGFP2-Orp1
Adenovirus encoding roGFP2-Orp1 under the control of
the cytomegalovirus (CMV) promoter was generated and
amplified using AdEasy System. The cDNA encoding the
probe was inserted in the pShuttle-CMV vector and then
recloned into the adenoviral backbone plasmid pAdEasy.
The resultant pAd-roGFP2-Orp1 was digested by PacI and
transferred in human embryonic kidney (HEK)-293 cells to
generate adenovirus particles. Adenovirus was amplified in
HEK-293 cells, purified on CsCl gradient, and quantified
using the Adeno-X Rapid Titer Kit (Clontech).
INS-1E cells were plated on glass coverslips and trans-
fected with a control siRNA or two different siRNAs tar-
geting rat TRMT10A. Two days after transfection and 48 h
before the fluorescencemeasurements the cells were infected
with adenovirus encoding roGFP2-Orp1.
For the dynamic measurements of roGFP2-Orp1, the
cell-containing coverslips were mounted in a perifusion
chamber maintained at 37◦C and placed on a ×40 objec-
tive of an inverted microscope. The cells were perifused at a
flow rate of ∼1 ml/min with a bicarbonate-buffered Krebs
solution containing 120 mM NaCl, 4.8 mM KCl, 2.5 mM
CaCl2, 24 mM NaHCO3, 1 g/l BSA (Fraction V, Roche)
and 10 mM glucose. This solution was continuously gassed
with O2/CO2 (94/6) to maintain the pH around 7.4. The
fluorescence ratio of roGFP2-Orp1 was measured every 30
s after double excitation, at 400 and 480 nm, and by using
an emission filter at 535 nm. The data were normalized to
the fluorescence ratiomeasured at the end of the experiment
in the presence of 10 mM DTT (set to 0%) then of 100 M
aldrithiol (set to 100%) to allow comparison between ex-
periments. Cells pretreated for 2 h with 15 M menadione
immediately before the measurements were used as positive
control.
Western blot
Cells were lysed in Laemmli buffer, extracts resolved on
10–14% SDS-PAGE and transferred to nitrocellulose mem-
brane (Bio-Rad). Immunoblotting was performed using
antibodies against cleaved caspase-9, Bcl-x(L), Bcl-2, cy-
tochrome c, CoxIV, -tubulin and GAPDH (the latter two
used as control for protein loading). After incubation with
secondary horseradish peroxidase-conjugated antibodies,
proteins were detected using SuperSignal West Femto
chemiluminescence revealing reagent (ThermoFisher) in a
ChemiDocXRS+ system and quantified by Image Lab soft-
ware (Bio-Rad). The antibodies and dilutions used are pro-
vided in Supplementary Table S14.
Immunofluorescence
Cells were fixed in 4% formaldehyde for 15–20 min, per-
meabilized with 0.5% triton-X100 for 10 min, blocked with
UltraV block (ThermoFisher) for 8–10 min and incubated
with primary antibodies diluted in 0.1% Tween in PBS for 3
hours at room temperature or overnight at 4◦C. Following
incubation for 30 min or 1 h at room temperature with sec-
ondary antibodies samples were mounted with Vectashield
with DAPI (Vector Laboratories) and covered with glass
coverslips. The antibodies and dilutions used are provided
in Supplementary Table S14.
Statistical analysis
Data are shown as means ± SE. Individual data points rep-
resent independent experiments. Non-normally distributed
variables were log-transformed before statistical testing.
Comparisons between two groups where done by paired t-
test, and between three ormore groups by one-wayANOVA
followed by two-sided Student’s paired t-test with Bonfer-
roni correction for multiple comparisons. Comparisons be-
tween control and TRMT10A-deficient patient cells were
made by unpaired t-test. Comparisons between control and
TRMT10A-deficient iPSC-derived -like cells were made
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by multiple t-test using the two-stage step-up method of
Benjamini, Krieger and Yekutieli, with false discovery rate
of 5%. A P value <0.05 was considered statistically signifi-
cant.
RESULTS
TRMT10A deficiency leads to decreased tRNA guanosine
methylation
Based on homology with yeast Trm10 (30), TRMT10A
is predicted to be a tRNA (guanosine) methyltrans-
ferase. In vitro methylation experiments using recombinant
TRMT10A (27,32) have previously shown that TRMT10A
has tRNA methyltransferase activity. To evaluate whether
TRMT10A deficiency indeed affects tRNA guanosine
methylation (m1G) in vivo, we purified small RNAs (<200
nucleotides) from lymphoblasts from three control individ-
uals, four TRMT10A-deficient patients (two with a ho-
mozygous c.379G>A; p.Arg127Stopmutation (24) and two
with a homozygous c.79G>T; p.Glu27Stop mutation (26)),
and three heterozygous TRMT10A mutation carriers. The
small RNA fraction contained two peaks of tRNAs, a sep-
arate microRNA (miRNA) smear region and very little
contaminant small ribosomal RNAs (by Agilent Bioan-
alyzer, Supplementary Figure S1A). m1G methylation in
these small RNAs, was measured by HPLC coupled to tan-
dem MS following complete RNA hydrolysis. In these ex-
periments, an m1G standard was used to identify the peak
corresponding to m1G in the digested RNA samples (Sup-
plementary Figure S1B). Patient lymphoblasts showed a
50% reduction in m1G compared to unaffected controls,
while a slight increase was observed in heterozygous carriers
(Figure 1A and B). To assess whether these m1G changes
occurred in tRNAs, we purified tRNAs (Supplementary
Figure S1C) and confirmed that m1G was 50% lower in pa-
tient compared to control lymphoblasts (Figure 1C). These
data confirm that TRMT10A is a tRNA methyltransferase
in humans, and demonstrate that tRNA methylation is sig-
nificantly reduced in TRMT10A-deficient cells.
tRNAGln and tRNAiniMeth are TRMT10A substrates
Yeast Trm10 methylates tRNAs in G9 (30). In the Mod-
omics database (http://modomics.genesilico.pl/), the two
cytosolic human tRNAs for glutamine, tRNAGln(UUG)
and tRNAGln(CUG) (with minor sequence differences), and
tRNAiniMeth(CAU) have a methylated G9. Since HPLC/MS
analysis does not indicate in which position the tRNA is
methylated (analysis performed after RNA hydrolysis), we
performed primer extension assays (30) to assess whether
human TRMT10Amethylates these tRNAs in G9. This ap-
proach relies on steric hindrance by m1G9 that prevents G–
C Watson–Crick base pairing and attenuates primer exten-
sion during reverse transcription (Figure 1D). Primer ex-
tension assays using oligonucleotides annealing both glu-
tamine tRNAs (tRNAGln(UUG/CUG)) and tRNAIniMeth(CAU),
showed longer amplicons in patient lymphoblasts com-
pared to controls (Figure 1E, H). For tRNAGln(UUG/CUG),
sequencing assays in patient and control samples confirmed
the identity of the retrotranscribed tRNA (Figure 1F, G)
and suggested that in control cells the retrotranscription
stops in G9, while in TRMT10A-deficient cells the tRNA
amplification continues towards the end of the tRNA, sug-
gesting that G9 is not methylated. For tRNAIniMeth(CAU)
the sequencing experiments failed to accurately assess the
identity of the primer extension stop due to poor resolu-
tion of the sequencing bands (data not shown). As men-
tioned above, the Modomics database indicates that m1G9
is present in tRNAIniMeth suggesting that the amplification
difference observed between patients and controls may be
the result of impaired m1G9 modification in TRMT10A-
deficient samples. tRNAHis(GUG), with a cytosine in position
9, was used as negative control in our assays (Figure 1I).
Based on an earlier report (46) we also developed a
real-time PCR-based assay to assess m1G9 (see schematic
representation, Figure 1J) in biological samples. This as-
say, also based on halted reverse transcription, is a fast
and not radioactive approach to determine m1G9 mod-
ification. Since other modifications such us m1A, m3C
or N2,N2-dimethylguanosine also block reverse transcrip-
tion (47) and may lead to false interpretation of the
results, we interrogated the Modomics database to as-
sess whether these other modifications where present in
tRNAGln(UUG/CUG) and tRNAIniMeth(CAU). m3C andN2,N2-
dimethylguanosine were reported to be absent in these tR-
NAs, while m1A was present in position 58. To prevent the
latter from interfering with the assay, the reverse primers
were designed to anneal in this region. In keeping with
the primer extension assays, significantly more amplifica-
tion was seen for tRNAGln(UUG/CUG) and tRNAIniMeth(CAU)
in small RNAs from TRMT10A-deficient patient lym-
phoblasts compared to controls (Figure 1K, L and Supple-
mentary Table S1), suggestive of reduced m1G9 modifica-
tion. TRMT10A haploinsufficiency did not have a signifi-
cant impact on m1G9 methylation (see heterozygous carrier
samples in Figure 1K, L). As expected, there were no differ-
ences in tRNAHis(GUG) PCR amplification between patient
and control lymphoblasts (Figure 1M).
To evaluate the impact of TRMT10A deficiency on
tRNA methylation in pancreatic -cells, we silenced
TRMT10A expression in clonal human EndoC-H1 -
cells (Figure 1N and Supplementary Table S2). As in
lymphoblasts, TRMT10A deficiency significantly reduced
m1G9 in tRNAGln(UUG/CUG) (Figure 1O and Supplemen-
tary Table S2), but the amplification difference was less
pronounced than in lymphoblasts. This may be the con-
sequence of the partial and transient TRMT10A knock-
down achieved in the silencing experiments (by 70 ±
3%, Figure 1N) compared to a complete and permanent
TRMT10A deficiency in patient cells. In keeping with
this, TRMT10A-silenced EndoC-H1 cells showed a non-
significant trend for reducedG9 in tRNAIniMeth(CAU) (Figure
1P). The tRNAHis(GUG) amplification profile was not differ-
ent between control and TRMT10A-silenced cells (Figure
1Q).
Establishment and characterization of iPSC-derived -like
cells
To investigate TRMT10A function in a more patient-
relevant -cell model, we established a 7-stage protocol to
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Figure 1. TRMT10A deficiency leads to decreased guanine 9 methylation (m1G9). Small RNAs (<200 bp) (A, B) and tRNAs (C) were purified from
lymphoblasts from two to four TRMT10A-deficient patients (PA), heterozygous mutation carriers (Hz) and two healthy controls (CT). m1G modification
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differentiate iPSCs into -like cells (Figure 2A). We used
one previously characterized control line (HEL46.11, CT1)
(38,48) and generated iPSCs from one TRMT10A patient
and an additional healthy control (HEL115.6, CT2). Char-
acterization of the novel TRMT10A and CT2 iPSC lines
confirmed expression of pluripotency markers, silencing
of exogenous transgenes, and in vitro differentiation into
the three principal germ layers (endoderm, mesoderm and
ectoderm) by embryoid body assay (Supplementary Fig-
ure S2A-D). The TRMT10A iPSCs had a normal kary-
otype (46, XX), and CT2 iPSCs had a 46, XY karyotype
with a Y chromosome duplication (Supplementary Figure
S2E-F). This was confirmed by band C staining, showing
the presence of two centromeres. Since the Y chromosome
bears very few loci except for male fertility, the duplica-
tion is not expected to affect the present results. The two
control and TRMT10A iPSCs differentiated into defini-
tive endoderm expressing SOX17 and subsequently pro-
gressed into pancreatic endoderm co-expressing pancreas
and duodenal homeobox 1 (PDX1) and NK6 Homeobox
1 (NKX6.1) (Figure 2B). Gene expression across differenti-
ation stages showed a normal developmental pathway with
increasing PDX1 andNKX6.1 expression, transient expres-
sion of SOX9 andNeurogenin3 (NGN3), followed by induc-
tion of its downstream genes NeuroD1 and NKX2.2 (Sup-
plementary Figure S3A-F). At the end of the differenti-
ation the islet-like aggregates expressed -cell-specific in-
sulin and glucagon-like peptide-1 receptor (GLP1R) and -
cell-specific glucagon (Figure 2E, F, Supplementary Figure
S3G). Immunofluorescence of stage 7 aggregates showed
more C-peptide-positive and less glucagon-positive cells in
the control cells compared to TRMT10A patient cells (Fig-
ure 2B, C). As in lymphoblasts (24), the patient cells had
very low TRMT10A mRNA expression, probably due to
mRNA decay (Figure 2D). Having validated the iPSC-
derived model, we examined tRNAGln and tRNAIniMeth G9
methylation. In keeping with the TRMT10A-deficient lym-
phoblasts and TRMT10A-silenced EndoC-H1 cells, the
modification of these tRNAs was significantly reduced in
TRMT10A-deficient -like cells; this was already present in
earlier stages of differentiation (Figure 2G, H). Collectively,
these results identify the cytosolic tRNAGln(UUG/CUG) and
tRNAIniMeth(CAU) as TRMT10A substrates in humans.
m1G9 modification is not essential for tRNA aminoacylation
To assess whether TRMT10A deficiency alters tRNA
aminoacylation, we measured incorporation of radiola-
beled L-[3,4–3H(N)]-glutamine and L-[35S]-methionine into
tRNAMeth and tRNAGln in lymphoblasts from controls
and TRMT10A-deficient patients. TRMT10A deficiency
did not modify amino acid incorporation (Supplementary
Figure S4A and B), suggesting that m1G9 is not required for
tRNA aminoacylation.
Hypomethylated tRNAs undergo fragmentation
We next examined whether methylation by TRMT10A
modulates tRNA fragmentation. For this purpose, we per-
formed Northern blots of TRMT10A-competent and -
deficient lymphoblasts using radiolabeled probes comple-
mentary to the 5′- or 3′-end of tRNAGln, the 5′-end of
tRNAIniMeth, and tRNAHis. tRNAGln but not tRNAIniMeth
was fragmented in TRMT10A-deficient cells, with accumu-
lation of 5′-tRFs of around 22 nucleotides and longer ones
probably corresponding to 5′-tiRNAs (Figure 3A, C). Us-
ing a 3′-tRNAGln probe, there was no difference in tRNA
fragmentation between patients and controls (Figure 3B),
suggesting that the 5′-tRNAGln fragments are probably the
consequence of controlled tRNA fragmentation rather than
tRNA degradation. This later process may produce multi-
ple bands that should have been detected by both 5′- and
3′-probes. The absence of increased 3′-tRNAGln fragments
in patient samples is also in good correlation with a tRNA
fragmentation process. It has been shown that the stability
of the generated tRNA halves can be asymmetric, meaning
that in some cases either 5′- or 3′-fragments are detected, the
other being rapidly degraded upon generation (49,50). The
integrity of the non-TRMT10A target tRNAHis was not al-
tered by TRMT10A deficiency (Figure 3D).
To confirm these findings, we quantified 5′-tRFsGln by
real-time PCR (Figure 3E and F) using miRCURY LNA™
Universal RT miRNA PCR system, originally designed to
detect miRNAs. Since the presence of m1A, m3C and m1G
may interfere with tRF quantification by impairing cDNA
synthesis, we pre-treated total RNA with the recombinant
demethylases AlkB and AlkB-D135S before reverse tran-
scription. AlkB efficiently demethylates m1A and m3C in
human tRNAs, while its mutated version AlkB-D135S has
enhanced demethylase activity against m1G (45). The ef-
←−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−
was evaluated by HPLC coupled to MS. (A) Representative MS profiles of small RNAs from one control and one TRMT10A-deficient patient. Upper
panel: methylated guanosine (m1G, arrow), lower panel: unmethylated guanosine (Guo). (B, C) m1G quantification in number of methylated guanosines
per 1000 guanosines (m1G/1000Guo). (D, E, H–I) Assessment of m1G9 by primer extension assays in specific tRNAs. (D) Schematic representation of the
assay. Red circle: G9; green circles: anticodon; black line: radiolabeled primer. m1G9 stops the reverse transcription (blue line, *). In the absence of m1G9
the reverse transcription continues towards the 5′ end of the tRNA (blue dotted line). (E, H and I) Primer extension assay for tRNAGln, tRNAIniMeth
and tRNAHis. (F) Sequencing lanes for tRNAGln. (G) Alignment of tRNAGln RNA and cDNA sequence, as read in the sequencing assay. Dots represent
regions where the sequence could not be assessed. Nucleotides in bold are predicted to be modified in Modomics. G in red: guanosine 9. Bk: primer-only
control; Pr, primers; PE stop, primer extension stop. The images are representative of 3–4 independent experiments. (J) Schematic representation of the
real-time PCR-based assay for m1G9 assessment. Small RNA (Step 1) was reverse transcribed using tRNA-specific reverse primers (Step 2). The cDNA
was used as template in real-time PCR using the primer combinations (Fw1 + Rev) and (Fw2 + Rev) (Step 3). (K–M) Real-time PCR data in lymphoblasts
from three controls (CT, n= 3–5 independent experiments per individual), three Hz (Hz, n= 3 per individual) and four TRMT10A-deficient patients (PA,
n= 2–3 per individual). (N–Q) TRMT10A was silenced in EndoC-H1 cells using two siRNAs targeting TRMT10A (#1 and #2); cells transfected with a
control siRNA were used as control (siCT). (N) TRMT10A mRNA expression assessed by real-time PCR and normalized to -actin. (O–Q) Assessment
of m1G9 by real-time PCR in control and TRMT10A-silenced EndoC-H1 cells. Data is expressed as 2−CT that represents relative amplification levels
of PA samples versus CT, or siTRMT10A cells versus siCT control cells. Bars show means ± SEM, and data points individual experiments. *P < 0.05,
siTRMT10A verus siCT; ***P < 0.001 PA versus CT by ANOVA followed by t-test with Bonferroni correction for multiple comparisons.
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Figure 2. TRMT10A-deficiency leads to impaired tRNA m1G9 in iPSC-derived -like cells. (A) Time line of iPSC differentiation into -like cells. (B)
Representative immunofluorescence and bright field images of two control (CT1 and CT2) and one TRMT10A-deficient iPSC line during -cell differen-
tiation. OCT4 and SOX17 were used as pluripotency and definitive endoderm markers, respectively, at the end of stage 1 (S1). NKX6.1 and PDX1 were
used as markers of pancreas progenitors (end of stage 4, S4). - and -like cells were identified by human C-peptide (C-pept) and glucagon (GCG) stain-
ing, respectively. The nuclei were visualized with DAPI. (C) Quantification of glucagon (GCG) and C-peptide single positive cells, and CGC + C-peptide
double positive cells in the immunofluorescence images. The results are expressed as proportion of total cell number and are means ± SEM of n = 3–5
independent experiments. (D–F) TRMT10A, insulin (INS) and glucagon-like peptide-1 receptor (GLP1R) mRNA expression assessed by real-time PCR
during iPSC differentiation in the two control (CT1 and CT2) and the TRMT10A deficient cell lines, EndoC-H1 cells and adult human islets. (G–H)
m1G9 in tRNAGln and tRNAIniMeth measured by real-time PCR. S0: iPSCs, S3–7, Stages 3 to 7. Bars show means ± SEM, and data points independent
experiments. #P < 0.05, differential gene expression between a given stage of the differentiation and the preceding one, by ANOVA followed by t-test
with Bonferroni correction for multiple comparisons. &P < 0.05, &&P < 0.01; &&&Control versus TRMT10A-deficient cells, by multiple t-test using the
two-stage step-up method of Benjamini, Krieger and Yekutieli, with FDR (Q) of 5%.
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Figure 3. TRMT10A deficiency leads to tRNAGln fragmentation. tRNA
fragmentation was analyzed by Northern blot using radiolabeled probes
targeting the 5′ region of tRNAGln, tRNAIniMeth and tRNAHis (A, C, D),
or the 3′ region of tRNAGln (B). Small 5′-tRNAGln fragments (tRFs) were
detected by real-time PCR (E,F). tRNAGln was fragmented in patient sam-
ples (PA) compared to controls (CT) evidenced by the accumulation of 5′-
(A) but not 3′- (B) -tRNAGln fragments. No difference in fragmentation
was observed for tRNAIniMeth (C) or tRNAHis (D). Pictures are represen-
tative autoradiographs of 2–3 independent experiments. (E, F) Quantifi-
cation of 5′-tRFGln by real time PCR in lymphoblasts from one control
and one TRMT10A-deficient patient (D), and iPSC-derived -like cells
from two controls and one TRMT10A-deficient patient (E). miRNA hsa-
let-7f-5p was used as reference RNA for normalization. Bars show means
± SEM, and data points independent experiments. *P < 0.05, **P < 0.01
Control versus TRMT10A-deficient cells, by t-test.
fectiveness of the demethylases was confirmed by measur-
ing tRNAGln m1G9 by real-time PCR: untreated patient
samples showed enhanced PCR amplification indicating
reduced m1G9 and this difference was lost by demethy-
lase treatment (Supplementary Figure S4C and D). In
agreement with the Northern blots, a significant increase
in 5′-tRFsGln was observed in TRMT10A-deficient lym-
phoblasts, and in TRMT10A-deficient iPSC-derived -like
cells (Figure 3E and F). Altogether these results demon-
strate that hypomethylated tRNAGln undergoes fragmenta-
tion.
Oxidative stress mediates apoptosis in TRMT10A-deficient
-cells
We have previously shown that TRMT10A silencing in-
duces -cell apoptosis (24). To elucidate the underlying
molecular mechanisms, we first silenced TRMT10A in
clonal rat INS-1E -cells using two siRNAs with compa-
rable knockdown efficiency and apoptosis induction (Fig-
ure 4A and B). TRMT10A silencing enhanced reactive oxy-
gen species (ROS) production, measured by oxidation of
the fluorescent probe DCF (Figure 4C). We also used the
more H2O2-specific Orp1-roGFP2 (51) and the OH•- and
peroxynitrite-specific fluorescent probe HPF (41). Orp1-
roGFP2 oxidation was unchanged by TRMT10A silenc-
ing (Supplementary Figure S5A), but HPF oxidation was
induced, indicative of OH• and peroxynitrite production
(Figure 4D). Peroxynitrite is formed by the interaction of
superoxide (O2•) and nitric oxide. No increase in nitric
oxide production, measured as accumulated nitrite in the
medium (52), was observed in TRMT10A-deficient INS-1E
cells (0.45 ± 0.06 M NO2− for siTRMT10A#3, 0.26 ±
0.05 MNO2− for siTRMT10A#4, 0.95 ± 0.34 MNO2−
for siCT, n = 3).
TRMT10A silencing also induced apoptosis in EndoC-
H1 -cells, assessed by nuclear dyes and caspase-3 cleav-
age (Figure 4E–G, Supplementary Figure S5B), and en-
hanced oxidative stress (HPF oxidation, Figure 4H). To as-
sess whether oxidative stress contributes to the observed
-cell apoptosis, we used the superoxide anion scavenger
4,5-dihydroxy-1,3-benzenedisulfonic acid (Tiron) and the
general antioxidant N-acetyl-L-cysteine (NAC). Both com-
pounds abolished -cell apoptosis induced by TRMT10A
deficiency (Figure 4I), demonstrating the important role of
oxidative stress.
iPSC-derived -like cells from controls and a
TRMT10A-deficient patient showed indistinguishable
basal viability (Figure 4J, untreated), possibly reflect-
ing an adaptive mechanism to constitutive TRMT10A
deficiency. In agreement with our previous findings in
TRMT10A-silenced clonal -cells (24), TRMT10A-
deficient iPSC--like cells showed enhanced sensitivity to
apoptosis induced by the ER stressor thapsigargin (Figure
4J–L).
The pro-apoptotic Bcl-2 protein Bim is a key mediator of
TRMT10A deficiency-induced -cell apoptosis
Oxidative stress can induce -cell death through activa-
tion of the intrinsic (mitochondrial) pathway of apopto-
sis (41). This pathway is controlled in -cells by anti- and
pro-apoptotic Bcl-2 proteins (53) and culminates withmito-
chondrial permeabilization, cytochrome c release, caspase-
9 and -3 activation and cell death (54–56). TRMT10A si-
lencing enhanced cytochrome c release to the cytosol and
induced caspase 9 cleavage in INS-1E (Figure 5A–D) and
EndoC-H1 cells (Figure 5G, H) confirming activation of
the intrinsic pathway of apoptosis. TRMT10A deficiency
increased mRNA expression of the pro-apoptotic proteins
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Figure 4. TRMT10A deficiency induces oxidative stress and sensitizes iPSC-derived -like cells to endoplasmic reticulum stress-induced apoptosis. INS-
1E cells (A–D) and EndoC-H1 cells (E–I) were transfected with control siRNA (siCT) or two siRNAs targeting rat TRMT10A (#3 and #4) or human
TRMT10A (#1 and #2). (A) TRMT10AmRNA expression was analyzed by real-time PCR and normalized to GAPDH expression. (B, E, I, J) Apoptosis
was examined by Hoechst 33342 and propidium iodide staining. (C, D, H) Oxidative stress was measured by oxidation of the fluorescent probes DCF and
HPF. Menadione-treated cells were used as positive control. (F, G) Immunofluorescence of cleaved caspase 3. (F) Representative images of three indepen-
dent experiments for siCT and siTRMT10A #1 (the full image is provided in Supplementary Figure S5B). (G) Percentage of cleaved caspase 3-positive
cells in the immunofluorescence images. (I) Apoptosis of control (siCT) and TRMT10A-deficient cells treated or not (-) with the ROS scavengers Tiron
and N-acetyl L-cystein (NAC). (J) Viability of control (CT) and TRMT10A-deficient iPSC--like cells treated for 48h with the ER stressor thapsigargin
(1 M). (K, L) Time course of thapsigargin-mediated apoptosis in control (CT) and TRMT10A-deficient iPSC--like cells. Early (K) and late apoptosis
(L) was assessed by Annexin V-mediated luminescence, and DNA binding dye-mediated fluorescence, respectively. n = 3–4 independent experiments. Bars
show means ± SEM, and data points independent experiments. *P < 0.05, siTRMT10A versus siCT; @P < 0.05, @@P < 0.01 ROS scavengers versus
untreated &P < 0.05, &&&P < 0.001, thapsigargin versus untreated; #P < 0.05, ###P < 0.001, iPSCCT versus iPSCTRMT10A by ANOVA followed by t-test
with Bonferroni correction for multiple comparisons.
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Figure 5. TRMT10A deficiency activates the intrinsic pathway of apoptosis, and induces expression and splicing of the pro-apoptotic protein Bim. INS-1E
(A–F, K), EndoC-H1 cells (G–J, L), and dispersed human islets (M) were transfected with control siRNA (siCT) or two siRNAs targeting rat (#3 and
#4) or human TRMT10A (#1 and #2) alone or in combination with one siRNA targeting rat or human Bim (siBim). (A–D, G–H) Western blots for
cytochrome c and cleaved caspase-9. (A, C, G) are representative blots and (B, D, H) densitometric quantification of the blots. Bim (E, I) and Bim small
(BimS) (F, J) mRNA expression was evaluated by real-time PCR and normalized to GAPDHor -actin expression. (K–M) apoptosis examined byHoechst
33342 and propidium iodide staining. Bars show means ± SEM, and data points individual experiments. *P < 0.05 siTRMT10A versus siCT, #P < 0.05
TRMT10A versus siTRMT10A-siBim by ANOVA followed by paired t-test with Bonferroni correction for multiple comparisons.
Bim (Figure 5E) and Bad (Supplementary Figure S6A) in
INS-1E cells, and enhanced Bim splicing into its most pro-
apoptotic form Bim small (BimS) in rat and human -cells
(Figure 5F, J). TRMT10A silencing did not modify ex-
pression of the pro-apoptotic proteins DP5 and PUMA
or the pro-survival proteins Bcl-2 and Bcl-x(L) (Supple-
mentary Figure S6B–G). To directly examine the role of
Bad or Bim in -cell apoptosis, we silenced TRMT10A
alone or together with Bim or Bad (Supplementary Figure
S6H–P). Bim, but not Bad, silencing prevented TRMT10A
deficiency-induced apoptosis in clonal rat and human -
cells and in primary human islets (Figure 5K–M, Supple-
mentary Figure S6P), identifying Bim as the key mediator
of -cell death.
5′-tRNAGln fragments induce -cell apoptosis
tRNA fragments modulate stress responses and apoptosis
(10,16). Since TRMT10A deficiency induces tRNAGln frag-
mentation (Figure 3), we examined whether 5′-tRNAGln
fragments mediate -cell apoptosis. For this purpose, we
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transfected TRMT10A-competent EndoC-H1 cells with
synthetic sense (SS) or antisense (AS) 5′-tiRNAGln and 5′-
tRFsGln. The efficiency of transfection, assessed using flu-
orescent 5′-tRNA fragments was 25 ± 0% for 5′-tiRNAGln
SS, 25± 8% for 5′-tiRNAGln AS, 16± 1% for 5′-tRFsGln SS,
and 16± 1% for 5′-tRFsGln AS (Supplementary Figure S7).
5′-tiRNAGln SS but not 5′-tiRNAGln AS induced EndoC-
H1 cell apoptosis, assessed by nuclear staining and cas-
pase 3 cleavage (Figure 6A-C). Transfection with short 5′-
tRFGln SS also induced -cell apoptosis albeit to a lesser ex-
tent (Figure 6D-F). These findings suggest that 5′-tRNAGln
fragments mediate TRMT10A deficiency-induced -cell
death. To confirm this, we transfected TRMT10A-deficient
EndoC-H1 cells with a locked nucleic acid-enhanced anti-
sense oligonucleotide targeting 5′-tRFsGln (LNA-5′-tRFGln
AS). This molecule with low toxicity and high binding affin-
ity for complementaryRNA is resistant to exo- and endonu-
cleases resulting in long-lasting antisense activity. Based on
its sequence it is expected to work as a 5′-tRNAGln frag-
ment inhibitor binding both 5′-tRFsGln and 5′-tiRNAGln.
This LNA-5′-tRFGln AS prevented apoptosis induced by
TRMT10A deficiency (Figure 6G), supporting the role of
5′-tRNAGln fragments in -cell apoptosis.
DISCUSSION
An increasing body of evidence associates mutations in
tRNAs or tRNA modifying enzymes with human disease
(18). So far no human disease has been linked to cy-
tosolic tRNA mutations, probably due to the presence of
multiple paralogs of cytosolic tRNA-encoding genes (57).
In contrast, a wide variety of disease-causing mutations
in mt-tRNA genes have been described (18). These mito-
chondrial mutations affect high energy-consuming tissues
such as muscle, nervous system and -cells. Some are as-
sociated with maternally inherited diabetes and deafness
(19,58–62), resulting in hypomodified mt-tRNAs with im-
paired function and stability, e.g. m.14692A>G that re-
duces mt-tRNAGlu pseudouridination at position 55, re-
sulting in tRNA degradation. This affects translation of
mitochondrial-encoded glutamic acid-rich proteins such
as subunits of respiratory complex I and IV leading to
mitochondrial dysfunction (19). Mutations in mitochon-
drial, cytosolic and nuclear- tRNA-modifying enzymes lead
to tRNA hypomodifications and disease. Recessive muta-
tions in TRMT10C, coding for the mitochondrial tRNA-
methyltransferase MRPP1, cause hypotonia, deafness, ele-
vated lactate levels and premature death (63). MRPP1 and
MRPP2 form a stable complex with m1R9 tRNA methyl-
transferase activity that methylates mt-tRNAs in either G
or A in position 9 (32). These two proteins associate with
MRPP3, forming the RNase P complex responsible for the
5′ cleavage of mt-tRNAs (64). TRMT10C mutations, lead-
ing to reduced MRPP1 levels, impair mt-tRNA process-
ing and induce respiratory chain dysfunction (63). Muta-
tions in TRIT1, a tRNA isopentenyltransferase responsi-
ble for i6A modification at position 37 of selected mito-
chondrial tRNAs, cause microcephaly, epilepsy and dia-
betes (65). Polymorphisms in the cytosolic tRNA modify-
ing enzyme CDKAL1 are associated with increased T2D
risk and reduced insulin secretion (20–23, 66), while non-
sense mutations in TRMT10A, a nuclear tRNA methyl-
transferase, cause young-onset diabetes and microcephaly
(24–28). The last three examples, associating mutations in
mitochondrial, cytosolic and nuclear tRNA-modifying en-
zymes with diabetes point to a particularly sensitivity of
pancreatic -cells to tRNA hypomodifications.
A previous study using in vitro methylation assays with
recombinant TRMT10A identified yeast tRNAGly(GCC)
and tRNAVal(UAC) as TRMT10A substrates (31). Here,
we confirm the role of TRMT10A as a human m1G9
tRNA methyltransferase, and identify tRNAGln(UUG/CUG)
and tRNAiniMeth(CAU) as TRMT10A substrates. The real-
time PCR assays showed that the amplification difference
between patients and controls was more pronounced for
tRNAGln(UUG/CUG) than tRNAIniMeth(CAU). This may be the
consequence of different amplification efficiencies by the
primer sets. Indeed, the presently used real-time PCR ap-
proach is a convenient tool to detect differences in tRNA
modification between patients and controls, but it is less re-
liable to assess the abundance of m1G9 modification in a
particular tRNA compared to others.
Reduced tRNA modifications can negatively impact
tRNA aminoacylation (2) but this was not the case for
hypomethylated tRNAGln(UUG/CUG) and tRNAIniMeth(CAU).
Impaired tRNA modifications can also affect tRNA stabil-
ity (2). Trm10 deficiency in yeast leads to tRNA destabi-
lization and rapid tRNA decay evidenced by complete cell
growth arrest in mutants upon exposition to 5-fluoroacyl
at 38◦C (67). Our data suggest that TRMT10A deficiency
in humans leads to tRNAGln(UUG/CUG) fragmentation, with
accumulation of 5′- but not 3′-tRNA fragments, suggesting
that m1G9 prevents tRNAGln cleavage. However, changes
in tRNA processing and/or tRNA decay cannot be for-
mally excluded. tRNA fragments are a new class of small
non-coding RNAs that modulate a number of cellular pro-
cesses (15,68). The cleavage by angiogenin of tRNAs into
tiRNAs is stress-mediated, but little is known about the
biogenesis of tRFs. It has been demonstrated that modifi-
cation of tRNA nucleotides may induce or prevent tRNA
cleavage (15). Deficiency of the cytosine tRNAmethyltrans-
ferases Nsun2 and Dnmt2 induces angiogenin-mediated
tiRNAs (16,69).We speculate that the absence of m1G9 ren-
ders tRNAGln prone to enzymatic cleavage, however, fur-
ther studies are required to unequivocally ascertain whether
tRNAGln fragmentation under TRMT10A deficiency is in-
deed mediated by angiogenin, Dicer, or other RNA pro-
cessing enzymes. tRFs may target the 3′ UTR of specific
mRNAs and repress their translation (70,71), and/or they
may bind complementary RNAs and form duplexes that
the canonical miRNA machinery recognizes and cleaves
(68,72). Some 5′-tiRNAs were shown to facilitate assembly
of stress granules leading to translational inhibition (11,73).
In mammals, a 19-nucleotide-long 5′-tRFGln represses the
translation of a subset of mRNAs (74). TRMT10A silenc-
ing in rat -cells induced a small increase in total pro-
tein synthesis (24) which argues against global transla-
tional repression, at least under control condition follow-
ing TRMT10A deficiency by RNA interference. We cannot
rule out the possibility that 5′-tRFsGln modulate translation
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Figure 6. 5′-tiRNAGln and 5′-tRFsGln induce apoptosis in EndoC-H1 cells. TRMT10A competent cells were transfected with a control siRNA (siCT),
synthetic oligonucleotides homologous to the 5′-half of tRNAGln in sense (5′-tiRNAGln SS) or antisense version (5′-tiRNAGln AS) (A–C), or shorter (18
oligonucleotides) 5′-tRNAGln fragments in sense (5′-tRFsGln SS) or antisense version (5′-tRFsGln AS) (D–F). (G) EndoC-H1 cells were transfected with
a control siRNA (siCT) or one siRNA targeting TRMT10A (siTRMT10A#2) alone or combined with the tRNAGln fragment inhibitor LNA-5′-tRFGln
AS. Apoptosis was examined by Hoechst 33342 and propidium iodide staining (A, D, G) and by immunofluorescence of cleaved caspase-3 (B, C, E, F).
(B, E) Representative pictures of three to five independent experiments, (C, D) percentage of cleaved caspase-3 positive cells. Results are means ± SEM.
Data points represent individual experiments. *P < 0.05, **P < 0.01, ***P < 0.001 5′-tiRNAGln SS or 5′-tRFGln SS versus siCT; &P < 0.05 si#2 versus
siCT; #P < 0.05 si#2 versus si#2/siBim, by ANOVA followed by t-test with Bonferroni correction for multiple comparisons.
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of some mRNAs, or that TRMT10A deficiency represses
global protein translation under stress conditions.
The iPSC data do not point to an overt -cell differ-
entiation defect of TRMT10A-deficient cells, but further
work is needed to explore a possible role of TRMT10A
in development. TRMT10A patients develop diabetes dur-
ing adolescence or young adulthood, suggesting they have
no major defect in -cell development. tRNA fragments
play a role in cell viability (16). Deficiency in Nsun2, caus-
ing microcephaly, leads to impaired cytosine 5 methyla-
tion of selected tRNA species and tRNA cleavage; the
accumulation of 5′-tiRNAs induces stress responses and
neuronal death (16). Here, we show that TRMT10A de-
ficiency induces -cell oxidative stress and Bim-mediated
mitochondrial apoptosis. The apoptosis outcome is pheno-
copied by introducing sense 5′-tRNAGln fragments (tiRNAs
and tRFs) in TRMT10A-competent -cells, and a stable
5′-tRFGln antisense inhibits TRMT10A deficiency-induced
apoptosis, indicating that tRNA hypomethylation and con-
sequent cleavage mediate -cell death. Transfection with
5′-tiRNAGln SS or 5′-tRFsGln SS did not induce oxidative
stress or Bim expression in EndoC-H1 cells, possibly re-
lated to the low tRNA fragment transfection efficiency (16–
25%). tRNAiniMeth was hypomodified but not fragmented in
TRMT10A-deficient cells.
In conclusion, we demonstrate here that TRMT10A de-
ficiency leads to tRNA fragmentation as a result of tRNA
hypomethylation in guanosine in position 9. This points to
a novel mechanism of pancreatic -cell demise in diabetes.
Since TRMT10A deficiency is also associated with micro-
cephaly, our findings may have broader implications, no-
tably related with neuronal loss during brain development.
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